| Literature DB >> 32357570 |
Kylie Karnebeek1,2, Jesse M Rijks1,2, Elke Dorenbos1,2, Willem-Jan M Gerver3, Jogchum Plat4, Anita C E Vreugdenhil1,2.
Abstract
Previous studies demonstrated that hyperglycemic glucose concentrations are observed in children that are overweight or have obesity. The aim of this study was to evaluate the effect of a 12 month lifestyle intervention on free-living glycemic profiles in children that were overweight or had obesity, and the association of the alterations with changes in cardiovascular risk parameters. BMI z-score, free-living glycemic profiles, continuous overlapping net glycemic action (CONGA), and cardiovascular parameters were evaluated before and after a multidisciplinary lifestyle intervention, in 33 non-diabetic children that were overweight or had obesity. In children with a decrease in BMI z-score, the duration which glucose concentrations were above the high-normal threshold (6.7 mmol/L) and the glycemic variability decreased significantly. In these children, a decrease in median sensor glucose was associated with decreases in LDL-cholesterol, and systolic and diastolic blood pressure z-score. A decrease in BMI z-score was associated with a decrease in CONGA1, 2, and 4. In conclusion, the glycemic profiles in free-living conditions in children that were overweight improved in children with a decrease in BMI z-score after lifestyle intervention. In those children, changes in median sensor glucose concentrations were associated with changes in LDL-cholesterol and blood pressure z-scores. These results suggest that glucose homeostasis can improve after one year of lifestyle intervention and that these improvements are associated with improvements in cardiovascular health parameters.Entities:
Keywords: childhood obesity; continuous glucose measurement; glucose metabolism; lifestyle intervention
Mesh:
Substances:
Year: 2020 PMID: 32357570 PMCID: PMC7282030 DOI: 10.3390/nu12051228
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of the study participants at baseline and after 12 months of lifestyle intervention.
| Characteristics | Baseline | After 12 Months of Intervention |
|---|---|---|
| Age, years | 12.5 ± 3.2 | 13.8 ± 3.0 |
| BMI | 3.53 ± 0.66 | 3.46 ± 0.67 |
| Overweight/obesity/morbid obesity, % | 9/42/49 | 15/39/46 * |
| Waist circumference | 6.85 ± 2.43 | 7.33 ± 2.12 * |
| Median sensor glucose, mmol/L | 5.0 (3.2–7.3) | 5.1 (3.6–6.9) |
| Maximum sensor glucose, mmol/L | 7.2 (5.6–11.2) | 7.0 (5.4–9.9) |
| Minimum sensor glucose, mmol/L | 3.4 (2.2–4.4) | 3.4 (2.2–4.9) |
| Sensor glucose area under the curve | 14867 ± 1447 | 14746 ± 1586 |
| CONGA1 | 0.57 (0.39–1.31) | 0.50 (0.30–1.08) * |
| CONGA2 | 0.72 (0.46–1.61) | 0.69 (0.30–1.58) |
| CONGA4 | 0.88 (0.45–2.02) | 0.87 (0.39–1.94) |
| CV, % | 15.7 ± 5.5 | 15.1 ± 4.0 |
| Fasting glucose, mmol/L | 4.0 ± 0.5 | 4.0 ± 0.5 |
| Fasting insulin, mU/L | 18.5 ± 9.2 | 25.6 ± 13.7 * |
| HOMA-IR | 3.31 ± 1.61 | 4.29 ± 2.30 * |
| HbA1c, % | 5.4 | 5.2 ± 0.4 * |
| Plasma glucose 2 hours after glucose load, mmol/L | 5.5 ± 1.2 | 5.6 ± 1.1 |
| Total cholesterol, mmol/L | 4.8 (3.5–6.6) | 4.5 (3.5–6.9) * |
| LDL-cholesterol, mmol/L | 3.1 (2.0–4.5) | 2.7 (1.7–4.6) * |
| HDL-cholesterol, mmol/L | 1.1 (0.8–1.9) | 1.1 (0.8–1.9) |
| Triglycerides, mmol/L | 1.21 (0.39–4.48) | 1.13 (0.51–3.77) |
| Systolic blood pressure | 0.19 ± 1.26 | 0.02 ± 1.16 |
| Diastolic blood pressure | −0.37 ± 0.88 | −0.66 ± 1.17 |
Data are presented as mean ± SD or as median (minimum–maximum). * = significant between parameters at baseline compared to parameters after 12 months of intervention. CONGA = continuous overlapping net glycemic action; CONGA presented for 1-, 2-, or 4-hour time differences; CV = coefficient of variation; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance.
Characteristics of the study participants at baseline and after 12 months of lifestyle intervention stratified for change in BMI z-score.
| Decrease in BMI | Increase in BMI | |||
|---|---|---|---|---|
| Baseline | 12 Months of Intervention | Baseline | 12 Months of Intervention | |
| Age | 11.3 ± 2.6 | 12.7 ± 2.5 | 14.4 ± 3.1 | 15.6 ± 3.0 |
| BMI | 3.54 ± 0.62 | 3.30 ± 0.61 * | 3.50 ± 0.74 | 3.71 ± 0.71 * |
| Waist circumference | 6.3 ± 1.9 | 6.9 ± 1.6 | 7.6 ± 3.4 | 8.2 ±3.1 |
| Fasting glucose, mmol/L | 4.1 ± 0.6 | 4.3 ± 0.4 | 3.9 ± 0.5 | 4.1 ± 0.6 |
| Fasting insulin, mU/L | 18.1 ± 7.0 | 20.7 ± 9.8 | 20.2 ± 12.4 | 27.5 ± 13.3 * |
| HOMA-IR | 3.21 ± 1.40 | 4.00 ± 2.00 | 3.20 ± 1.84 | 4.50 ± 2.48 |
| HbA1c, % | 5.4 ± 0.3 | 5.2 ± 0.4 * | 5.5 ± 0.2 | 5.2 ± 0.4 * |
| Plasma glucose 2 hours after glucose load, mmol/L | 5.6 (3.9–7.5) | 5.6 (4.2–6.7) | 4.8 (2.9–6.3) | 5.2 (4.2–8.5) |
| Total cholesterol, mmol/L | 5.0 ± 0.9 | 4.4 ± 0.6 * | 4.9 ± 0.7 | 5.0 ± 0.9 |
| LDL-cholesterol, mmol/L | 3.2 ± 0.8 | 2.7 ± 0.6 * | 2.9 ± 0.7 | 3.0 ± 0.7 |
| HDL-cholesterol, mmol/L | 1.1 ± 0.2 | 1.2 ± 0.2 | 1.3 ± 0.4 | 1.2 ± 0.3 |
| Triglycerides, mmol/L | 1.23 (0.49–3.11) | 1.02 (0.51–3.69) | 1.20 (0.39–4.48) | 1.28 (0.65–3.77) |
| Systolic blood pressure | 0.23 ± 1.09 | −0.11 ± 1.07 | 0.11 ± 1.63 | 0.21 ± 1.37 |
| Diastolic blood pressure | −0.55 ± 0.65 | −0.89 ± 1.23 | −0.17 ± 1.15 | −0.16 ± 0.95 |
Data are presented as mean ± SD or as median (minimum–maximum). * = significant difference between parameters at baseline compared to parameters after 12 months of intervention. HOMA-IR = homeostatic model assessment of insulin resistance.
Figure 1Total minutes per 48 hours that sensor glucose concentrations were within specific glucose thresholds for the whole study population, at baseline and after 12 months of lifestyle intervention.
The 48-hour sensor glucose measurements stratified for changes in BMI z-score.
| Decrease in BMI | Increase in BMI | |||
|---|---|---|---|---|
| Baseline | After 12 Months of Intervention | Baseline | After 12 Months of Intervention | |
| Median sensor glucose, mmol/L | 4.9 (3.2–7.3) | 4.9 (3.6–5.9) | 5.0 (3.7–6.1) | 5.1 (3.6–6.9) |
| Maximum sensor glucose, mmol/L | 7.0 (6.0–9.5) | 6.9 (5.4–8.7) | 7.5 (5.6–11.2) | 7.3 (5.9–9.9) |
| Minimum sensor glucose, mmol/L | 3.4 (2.2–4.4) | 3.3 (2.6–4.8) | 3.3 (2.2–3.9) | 3.6 (2.2–4.9) |
| Time in level 2 hypoglycemic range (<3.0 mmol/L), minutes | 0 (0–265) | 0 (0–250) | 0 (0–395) | 0 (0–135) |
| Time in level 1 hypoglycemic range (3.0–3.9 mmol/L), minutes | 58 (0–690) | 0 (0–650) | 85 (0–870) | 45 (0–1270) |
| Time in target range (3.9–10.0 mmol/L), minutes | 2823 (2050–2880) | 2710 (2195–2880) | 2795 (1615–2880) | 2835 (1545–2880) |
| Time in secondary target range (3.9–7.8 mmol/L), minutes | 2735 (1945–2880) | 2703 (2195–2880) | 2655 (1615–2880) | 2560 (1545–2880) |
| Time in high-normal range (≥6.7 mmol/L), minutes | 38 (0–895) | 7 (0–123) * | 205 (0–840) | 22 (0–210) |
| Time in high-normal range (≥7.8 mmol/L), minutes | 0 (0–190) | 0 (0–170) | 0 (0–185) | 0 (0–345) |
| Time in level 1 hyperglycemic range (>10.0 mmol/L), minutes | 0 (0–0) | 0 (0–0) | 0 (0–40) | 0 (0–0) |
| Time in level 2 hyperglycemic range (>13.9 mmol/L), minutes | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Sensor glucose area under the curve | 14729 ± 1214 | 14419 ± 1301 | 15080 ± 1780 | 15249 ± 1891 |
| CV, % | 15.1 ± 5.4 | 14.5 ± 2.7 | 16.7 ± 5.6 | 16.1 ± 5.3 |
| CONGA1 | 0.56 (0.39–1.00) | 0.49 (0.30–1.00) * | 0.65 (0.39–1.31) | 0.60 (0.30–1.08) |
| CONGA2 | 0.70 (0.46–1.26) | 0.63 (0.39–1.16) * | 0.77 (0.46–1.61) | 0.71 (0.30–1.58) |
| CONGA4 | 0.83 (0.45–1.51) | 0.87 (0.48–1.31) | 0.95 (0.66–2.02) | 0.80 (0.39–1.94) |
Data are presented as mean ± SD or as median (minimum–maximum). * = significant difference between baseline and after 12 months of lifestyle intervention at the 0.05 level. CV = coefficient of variation; CONGA = continuous overlapping net glycemic action; CONGA presented for 1-, 2-, or 4-hour time differences.
Correlation coefficients between baseline characteristics and sensor glucose measurements—subgroup analysis for the children with a decrease in BMI z-score.
| Δ Median sensor glucose | Δ Maximum sensor glucose | Δ Minimum sensor glucose | Δ CONGA1 | Δ CONGA2 | Δ CONGA4 | Δ CV | Δ AUC | |
|---|---|---|---|---|---|---|---|---|
| Δ BMI | −0.127 | 0.502 * | −0.356 | 0.601 * | 0.643 * | 0.686 * | 0.620 * | 0.214 |
| Δ Fasting glucose | −0.067 | −0.241 | −0.342 | −0.095 | −0.076 | 0.03 | 0.350 | −0.416 |
| Δ Fasting insulin | 0.150 | −0.183 | −0.05 | −0.084 | 0.082 | 0.11 | 0.000 | 0.075 |
| Δ HOMA-IR | −0.072 | −0.034 | −0.023 | −0.179 | 0.216 | 0.191 | 0.197 | −0.038 |
| Δ HbA1c | 0.340 | 0.153 | −0.175 | 0.340 | 0.319 | 0.239 | 0.032 | 0.229 |
| Δ Glucose 2 h after glucose load | 0.027 | 0.144 | −0.412 | 0.155 | 0.236 | 0.292 | 0.490 | −0.259 |
| Δ Total cholesterol | 0.305 | 0.342 | −0.196 | 0.170 | 0.207 | 0.282 | 0.453 * | 0.162 |
| Δ LDL-cholesterol | 0.472 * | 0.150 | 0.029 | 0.166 | 0.045 | 0.021 | 0.111 | 0.214 |
| Δ HDL-cholesterol | 0.041 | 0.065 | −0.167 | −0.214 | −0.061 | 0.108 | 0.172 | 0.056 |
| Δ Triglycerides | −0.203 | 0.404 | −0.445 * | 0.228 | 0.433 | 0.520 * | 0.457 * | −0.117 |
| Δ Systolic blood pressure | 0.598 * | 0.268 | 0.095 | −0.033 | 0.019 | 0.020 | −0.104 | 0.498 * |
| Δ Diastolic blood pressure z-score | 0.605 * | 0.148 | 0.140 | 0.052 | 0.010 | −0.093 | −0.335 | 0.366 |
Correlations between variables were determined by Pearson’s correlation coefficient or Spearman’s correlation analysis, as appropriate, and were not corrected for other variables. * = significant correlation. Δ= delta; HOMA-IR = homeostatic model assessment of insulin resistance; CV = coefficient of variation; CONGA = continuous overlapping net glycemic action; CONGA presented for 1-, 2-, or 4-hour time differences; AUC = area under the curve.